Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis

PURPOSE: Although oral prednisolone is the first-line treatment for preventing recurrent optic neuritis (ON) after the completion of acute-phase treatment, especially anti-aquaporin 4 (AQP4) antibody-positive ON, and anti-myelin oligodendrocyte glycoprotein (MOG) antibody-positive ON, some patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Sotaro, Kurimoto, Takuji, Murai, Yusuke, Ueda, Kaori, Sakamoto, Mari, Chihara, Norio, Yamada-Nakanishi, Yuko, Nakamura, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883711/
https://www.ncbi.nlm.nih.gov/pubmed/33628473
http://dx.doi.org/10.1155/2020/8871146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883711/
https://www.ncbi.nlm.nih.gov/pubmed/33628473
http://dx.doi.org/10.1155/2020/8871146

Ejemplares similares